Jiří Bonaventura

Dr. Jiří Bonaventura

University Hospital in Motol, Prague, Praha, Hlavní Město, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
EPEva Polakova
Eva Polakova
VVVeronika Vejtasova
Veronika Vejtasova
JVJosef Veselka
Josef Veselka
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is considered a Mendelian disease, with mainly autosomal dominant inheritance. Most pathogenic variants are usually detected in genes for sarcomeric proteins. Nowadays, the genetic basis of HCM is believed to be rather complex. Thousands of mutations in more than 60 genes have been described in association with HCM. Nevertheless, screening large numbers of genes results in the identification of many genetic variants of uncertain significance and makes the interpretation of the results difficult. Patients lacking a pathogenic variant are now believed to have non-Mendelian HCM and probably have a better prognosis than patients with sarcomeric pathogenic mutations. Identifying the genetic basis of HCM creates remarkable opportunities to understand how the disease develops, and by extension, how to disrupt the disease progression in the future. The aim of this review is to discuss the brief history and recent advances in the genetics of HCM and the application of molecular genetic testing into common clinical practice.

1 January 2019 in Archives of Medical Science
Verified
Journal Article
Open access
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
PNPatricia Norambuena
Patricia Norambuena
PTPavol Tomašov
Pavol Tomašov
DJDenisa Jindrová
Denisa Jindrová
HŠHana Šedivá
Hana Šedivá
JVJosef Veselka
Josef Veselka
Introduction The yield of genetic testing in hypertrophic cardiomyopathy (HCM) is variable. The Mayo HCM Genotype Predictor score (Mayo Score) provides the pre-test probability of a positive HCM genetic test. In the original cohort of Mayo Score patients, only 9 HCM-associated myofilament genes...

21 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
EREthan Rowin
Ethan Rowin
RCRaymond H. Chan
Raymond H. Chan
Michael T. ChinMichael T. Chin
Michael T. Chin
VVVeronika Vejtasova
Veronika Vejtasova
MMMartin S. Maron
Martin S. Maron
Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events. Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.

20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
EREthan Rowin
Ethan Rowin
MMMartin S. Maron
Martin S. Maron
BMBarry J. Maron
Barry J. Maron

1 January 2016 in Archives of Medical Science
Verified
Journal Article
Open access
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
DADavid Alan
David Alan
JVJiri Vejvoda
Jiri Vejvoda
JHJakub Honek
Jakub Honek
JVJosef Veselka
Josef Veselka
In spite of many years of development and implementation of pre-hospital advanced life support programmes, the survival rate of out-of-hospital cardiac arrest (OHCA) used to be very poor. Neurologic injury from cerebral hypoxia is the most common cause of death in patients with OHCA. In the past...

8 December 2022 in The American Journal of Medicine
Verified
Journal Article
Closed access
Jiří BonaventuraJiří Bonaventura
Jiří Bonaventura
EREthan J. Rowin
Ethan J. Rowin
MMMartin S. Maron
Martin S. Maron
BMBarry J. Maron
Barry J. Maron